重度哮喘合并慢性自发性荨麻疹对奥马珠单抗和度普利尤单抗难治的病例报告
本文报道1例重度哮喘合并慢性自发性荨麻疹患者,先后接受3种生物制剂治疗。通过分析临床特征演变与治疗方案调整,最终明确有效治疗方案,为伴有共病的重度哮喘患者生物制剂选择及个体化治疗提供参考。
要点
- 重度哮喘合并共病时生物靶向药物精准选择仍面临挑战
- 部分重度哮喘患者对生物制剂初始应答不佳,转换是常用策略
- 本病例先后使用3种生物制剂,最终明确有效治疗方案
核心结论
- 本病例通过先后使用3种生物制剂并调整方案,最终明确有效治疗策略,为重度哮喘合并共病患者生物制剂选择提供参考。
研究设计与样本
- 病例报告,报道1例重度哮喘合并慢性自发性荨麻疹患者先后接受3种生物制剂治疗。
主要发现
- 患者先后接受3种不同生物制剂治疗,通过分析临床特征演变与治疗方案调整最终明确有效治疗方案。
关键数值与推荐
- GINA 2025版及我国《支气管哮喘防治指南(2024版)》推荐:高剂量ICS联合LABA治疗后症状仍控制不佳者,将已获批生物靶向制剂作为附加治疗。
- 部分生物靶向药物亦适用于慢性自发性荨麻疹、特应性皮炎、慢性鼻窦炎伴鼻息肉及变应性鼻炎等过敏性疾病。
临床怎么用
- 对伴有共病的重度哮喘患者,可参考本病例的生物制剂转换与个体化治疗思路进行选择。
局限性
- 本文为单例病例报告,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biological targeted drugs play an important role in the treatment of severe bronchial asthma. According to the Global Initiative for Asthma (GINA) 2025 Report and the Chinese Guidelines for the Diagnosis and Management of Bronchial Asthma (2024 Edition), for patients with poorly controlled symptoms despite treatment with high-dose inhaled corticosteroids (ICS) combined with long-acting β2-agonists (LABAs), approved biological targeted agents are recommended as add-on therapy. In addition, some of these agents are also indicated for allergic and immune-mediated conditions, including chronic spontaneous urticaria, atopic dermatitis, chronic rhinosinusitis with nasal polyps, and allergic rhinitis. However, in clinical practice, the precise selection of biological targeted drugs remains challenging in patients with severe asthma complicated by comorbidities. Although biologics can substantially improve the prognosis of some patients with severe asthma, a notable proportion still show a suboptimal initial response. Therefore, switching between biologics has become a common clinical strategy. Here, we report a patient with severe asthma complicated with chronic spontaneous urticaria who received three different biological agents sequentially. By analyzing the evolution of clinical characteristics and the adjustment made to the therapeutic regimens, we ultimately identified an effective treatment strategy. This case is intended to provide a reference for the selection of biologics and individualized treatment in patients with severe asthma and concomitant comorbidities. 生物靶向药物在重度支气管哮喘的治疗中具有重要地位。根据全球哮喘防治创议(GINA)2025版及我国《支气管哮喘防治指南(2024版)》,对于经高剂量吸入性糖皮质激素(ICS)联合长效β2受体激动剂(LABA)治疗后症状仍控制不佳的患者,推荐将已获批的生物靶向制剂作为附加治疗方案。此外,部分该类药物亦适用于慢性自发性荨麻疹、特应性皮炎、慢性鼻窦炎伴鼻息肉及变应性鼻炎等过敏性疾病。然而,临床实践中,对于伴有共病的重度哮喘患者,生物靶向药物的精准选择仍面临挑战。尽管生物制剂可显著改善部分重度哮喘患者的预后,但仍有部分患者初始应答不佳,因此生物制剂的转换已成为临床常用策略。本文报道1例先后接受3种生物制剂治疗的重度哮喘合并慢性自发性荨麻疹患者,通过分析其临床特征演变与治疗方案调整过程,最终明确有效治疗方案,以期为伴有共病的重度哮喘患者生物制剂选择及个体化治疗提供参考。.
引用
- Qu TG, Yi SW, Deng YQ, et al. [Dupilumab for severe asthma complicated with chronic spontaneous urticaria refractory to omalizumab and mepolizumab: a case report]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 42236460. doi:10.3760/cma.j.cn112147-20251203-00764
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。